Synergy Pharmaceuticals Inc. (NASDAQ: SGYP)
Synergy Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel gastrointestinal (GI) therapies.
We are committed to scientifically driven innovation, providing novel treatment options for patients and healthcare providers, rewarding opportunities for our employees, and creating exceptional value for our shareholders.
We have pioneered discovery, research and development efforts on analogs of uroguanylin, a naturally occurring human GI peptide, for the treatment of GI diseases and disorders. We discovered, are developing and control 100% worldwide rights to our proprietary uroguanylin analog platform that includes one commercial product, TRULANCE™ (plecanatide), and a second lead product candidate - dolcanatide.
TRULANCE™ is now FDA approved for the treatment of adults with chronic idiopathic constipation (CIC). We have also completed two Phase 3 clinical trials for TRULANCE in irritable bowel syndrome with constipation (IBS-C) and plan to file a New Drug Application Supplement with Clinical Data (sNDA) this quarter with an expected 10-month review period from submission.
Dolcanatide is our second uroguanylin analog currently being explored for ulcerative colitis.
We are based in New York City, with research, technical operations and commercial offices in suburban Philadelphia. Synergy [SGYP] became a public company in July 2008 and is currently listed on NASDAQ.